Effect of Prucalopride in Patients With Severe Chronic Idiopathic Constipation

This study has been completed.
Sponsor:
Information provided by:
Movetis
ClinicalTrials.gov Identifier:
NCT00576511
First received: December 17, 2007
Last updated: May 28, 2008
Last verified: December 2007
  Purpose

The purpose of this study is to determine whether prucalopride is safe and effective in patients with severe chronic constipation.


Condition Intervention Phase
Chronic Constipation
Drug: prucalopride
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Severe Chronic Constipation

Resource links provided by NLM:


Further study details as provided by Movetis:

Primary Outcome Measures:
  • Constipation severity (VAS) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Stool frequency (stool/week) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Enrollment: 53
Study Start Date: December 1994
Study Completion Date: February 1996
Primary Completion Date: February 1996 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Prucalopride
Drug: prucalopride
4 mg o.d.
Other Name: Resolor
Placebo Comparator: 2 Drug: placebo
Placebo o.d.

Detailed Description:

This is a phase II trial with a parallel-group design, consisting of a run-in phase (phase I), followed by a placebo controlled double-blind phase (phase 2). Patients will receive either R093877 4 mg or placebo o.d. for a period of 4 weeks.

Phase 1 is a run-in period of 4 weeks duration, during which the bowel habit is documented and the existence of constipation determined. If the definition of constipation was not met during the 4 weeks of the run-in period, double-blind treatment will not be started.

Phase 2 is a double-blind, randomized, placebo-controlled phase, in which patients will be treated for 4 weeks with either 4 mg of R093877 or placebo given o.d. (two capsules of 2 mg are taken before breakfast).

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients were eligible for inclusion if they were aged 18-75 years with a history of constipation, defined as the occurrence 2 of the following criteria during the previous 6 months or more:

    • 2 spontaneous (i.e. not induced by a laxative within 24 hours) bowel movements per week;
    • 25% of stools were lumpy and/or hard;
    • sensation of incomplete evacuation following 25% of stool;
    • straining at defaecation for 25% of the time.

All the patients screened for the study were dependent on osmotic laxatives (macrogol, milk of magnesia, lactulose), paraffin oil, glycerol or stimulant laxatives (antranoids, diphenylmethanes) given orally or rectally. The osmotic laxatives were taken on a daily base while the stimulant laxatives were restricted to 2, eventually 3 intakes per week. And although these laxatives, all or not combined promoted defaecation in the majority of patients, these regimens did not provide relief of constipation symptoms in none of the patients. Furthermore, many patients reported that the effect of the laxatives declined over time, that the intake of even stimulant laxatives was not consistently followed by rectal evacuation or that the intake of even stimulant laxatives was not consistently followed by rectal evacuation of that the dose and frequency of intake of laxatives had to be limited because of intolerable side effects including vomiting and abdominal cramps.

Eligible patients were also required to have constipation causing disability, with the patient's occupational, social and recreational activities governed by constipation and efforts to attain relief, and to have poor results with laxative treatment and diet counseling as determined by physician interview.

Patients also had to have a normal electromyographic inhibition pattern of the external anal sphincter during straining (assessed at the start of the treatment phase) and an absence of organic abnormalities of the colon (as assessed by barium enema or total colonoscopy).

Exclusion Criteria:

  • Drug-induced constipation
  • Secondary causes of constipation
  • Known or suspected organic large bowel disorders
  • Congenital or acquired megacolon/megarectum
  • History of previous abdominal surgery
  • Evidence of a non-relaxing pelvic floor as the main cause of constipation
  • Active proctological conditions
  • Impaired renal function or clinically significant abnormalities of blood chemistry, hematology, urinalysis or ECG.
  • Patients who were pregnant, breast feeding, not using acceptable methods of birth control or who had known illnesses or conditions that might interfere with adequate assessment of the study drug were also excluded.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00576511

Sponsors and Collaborators
Movetis
Investigators
Principal Investigator: Georges Coremans, MD Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University Leuven, Leuven
  More Information

Publications:
Responsible Party: Renate Specht Gryp, Movetis
ClinicalTrials.gov Identifier: NCT00576511     History of Changes
Other Study ID Numbers: PRU-BEL-6
Study First Received: December 17, 2007
Last Updated: May 28, 2008
Health Authority: Belgium: Institutional Review Board

Keywords provided by Movetis:
Constipation
Prucalopride
Colonic Transit Time

Additional relevant MeSH terms:
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms

ClinicalTrials.gov processed this record on April 17, 2014